FDA approves Xtandi for non-metastatic castration-sensitive prostate cancer with biochemical recurrence

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

The Pazdurs in their garden with their dog, Cleo. The dog’s full name is Cleopatra, Queen of Denial.In 1999, Rick Pazdur went in for a “perfunctory” final interview at FDA. Thinking it would only take a few minutes, his wife, Mary, decided to wait and have a quick cup of coffee at a nearby restaurant—Hooters.

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

In a move advertised as being in line with FDA’s goal of “radical transparency,” the agency July 10 announced the publication of more than 200 complete response letters.

July 11, 2025

Vol.51 No.27

By Jacquelyn Cobb

Funding Opportunities

NCI, SITC immunotherapy fellowship calls for applications

NCI and the Society for Immunotherapy of Cancer are accepting applications for a one-year fellowship program beginning in July 2026.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

Pfizer Inc. and Astellas Pharma Inc. announced positive topline results from the overall survival analysis from the phase III EMBARK study evaluating Xtandi (enzalutamide), an androgen receptor signaling inhibitor, in combination with leuprolide, and as a monotherapy in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer patients treated with immunotherapy, are the main reason certain immunotherapies may fail in treating the disease, according to research led by researchers at Keck Medicine of USC.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA preclinical study finds

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor-induced type 1 diabetes using an existing class of autoimmune drugs.

July 11, 2025

Vol.51 No.27

FDA approves Xtandi for non-metastatic castration-sensitive prostate cancer with biochemical recurrence

YOU MAY BE INTERESTED IN

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

NCI, SITC immunotherapy fellowship calls for applications

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA preclinical study finds

Renew today!

Subscriber content

Never miss an issue!

Login

FDA approves Xtandi for non-metastatic castration-sensitive prostate cancer with biochemical recurrence

YOU MAY BE INTERESTED IN

Rick and Mary Pazdur on facing “the other side of the stethoscope”A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

NCI, SITC immunotherapy fellowship calls for applications

Xtandi + leuprolide improves OS in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, phase III data show

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA preclinical study finds

Never miss an issue!

Login

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology